A New Targeted Pill for Metastatic Pancreatic Cancer: What the FDA Approval of Daraxonrasib Means for Patients

For decades, metastatic pancreatic cancer has been one of the hardest cancers to treat. After first-line chemotherapy stops working, options have been limited, and typical survival with second-line chemotherapy has been about 6 to 7 months. That landscape has now changed. 

The FDA approved daraxonrasib, an oral medicine that targets RAS, the molecular “on switch” that drives most pancreatic cancers. The approval is based on RASolute 302, a large international trial that compared this new pill with standard chemotherapy in people whose metastatic pancreatic cancer had already progressed after one prior treatment.

Why RAS Matters in Pancreatic Cancer

More than 90% of pancreatic ductal adenocarcinomas (the most common type of pancreatic cancer) carry a change in a family of genes called RAS. RAS proteins sit inside the cell and help control growth. When they are stuck in the “on” position, they keep sending grow-and-spread signals.

For years, RAS was considered “undruggable.” The protein’s surface did not offer an easy place for a medicine to target. Daraxonrasib works differently from older chemotherapy. It is a RAS(ON) multi-selective inhibitor, meaning the drug is designed to interrupt the main growth engine of pancreatic cancer rather than simply attacking rapidly dividing cells the way traditional chemotherapy does.

What RASolute 302 Studied

RASolute 302 enrolled adults with metastatic pancreatic adenocarcinoma who had already received one line of systemic therapy. Patients were randomly assigned to receive daraxonrasib 300 mg by mouth once daily or investigator’s choice of standard second-line chemotherapy.

About 92% of participants had a RAS G12 mutation, the most common RAS change in this disease. The trial also included people with other RAS changes and a small number without an identified RAS mutation. The main question was whether daraxonrasib would help people live longer (overall survival) and stay free of cancer growth longer (progression-free survival) than chemotherapy.

Results were published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology Annual Meeting. 

In the overall study population:

• Median overall survival nearly doubled at 13.2 months with daraxonrasib versus 6.7 months with chemotherapy.
• Median progression-free survival was 7.2 months versus 3.6 months, respectively.
• Tumor shrinkage of 30% or more occurred in about 30% of people on daraxonrasib versus 11% on chemotherapy.

Benefit was seen across age, sex, performance status, sites of metastases, and prior chemotherapy type. People on daraxonrasib also went longer before pain worsened and before overall quality of life declined.

The approval covers adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or those who are not candidates for multi-agent chemotherapy. Patients are not required to have a documented RAS mutation per the FDA label.

How Daraxonrasib is Taken

Daraxonrasib is taken as 300 mg once daily. Treatment continues until the cancer starts growing again or side effects become too difficult to manage.

Dose reductions to 200 mg and then 150 mg are built into the prescribing information if side effects occur. Many people in the trial needed a brief pause or a lower dose, most often for rash or mouth sores, and then continued on the therapy.

Clinicians typically start skin-protective measures at treatment initiation: moisturizer, a topical steroid on the face and chest, sunscreen, sun avoidance, and sometimes a preventive antibiotic such as doxycycline. 

Daraxonrasib: Why the Approval Matters

Second-line chemotherapy in metastatic pancreatic cancer has historically offered modest benefit and a heavy side effect burden. An oral targeted option that roughly doubles survival, nearly triples the chance of meaningful tumor shrinkage, delays pain, and is less often stopped for toxicity is a genuine change in the standard of care.

It is also the first approved therapy that directly targets RAS in pancreatic cancer. This is important as RAS has been the “missing lock” in this disease for a long time. This creates a new foundation for future research.

However, this is not a cure, and many people will eventually develop resistance. Ongoing studies are looking into treatment options for when a patient develops resistance. In addition, access, cost, and insurance coverage will matter in the months ahead. 

Next Steps in Pancreatic Cancer 

Approval of second-line daraxonrasib is the beginning of a new treatment era. Ongoing clinical trials are investigating how daraxonrasib may be used earlier in therapy and after surgery. The phase 3 RASolute 303 trial is enrolling people with newly diagnosed metastatic disease. The trial compares three approaches: daraxonrasib alone, daraxonrasib plus gemcitabine/nab-paclitaxel followed by daraxonrasib maintenance, and chemotherapy alone. Early-phase data suggested high response rates with both monotherapy and the combination of daraxonrasib and chemotherapy in the first-line setting. RASolute 303 will show whether starting RAS blockade up front, with or without chemotherapy, is better than waiting until after first-line chemotherapy fails.

In the RASolute 304 trial, researchers are testing daraxonrasib as maintenance after surgery and chemotherapy in earlier-stage disease, asking whether shutting off RAS can reduce the chance of the cancer coming back.

Researchers are also working to better understand who benefits most. In RASolute 302, benefit was seen in patients with and without a documented RAS mutation. Researchers still need to understand which rare molecular subgroups benefit least, how to manage acquired resistance, and how to support patients who may not be able to tolerate therapy. 

A practice-changing pill only helps if people can get it. Patient-support programs, rapid insurance decisions, community-oncology education, and clear guidance on skin and mouth care will be important to help translate the clinical trial benefit seen to individuals in the community.

Pancreatic cancer treatment is moving from sequential chemotherapy until options are exhausted toward a more targeted strategy, now more in line with other cancers. 

This is hopefully just the beginning to more major breakthroughs for the treatment of pancreatic cancer. 

This summary is for educational purposes and is based on the FDA approval of daraxonrasib, the published RASolute 302 results, and publicly reported follow-on trials. It is not a substitute for personalized medical advice. Always consult your healthcare providers for guidance specific to your care.